Mevof Uses

sponsored
Did you have any side effects with this medicine?

What is Mevof?

Mevof injection is used to treat bacterial infections in many different parts of the body. It is also used to prevent an anthrax infection after a person has been exposed to anthrax. Mevof is also used to treat and prevent plague (including pneumonic and septicemic plague).

Mevof belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. However, Mevof will not work for colds, flu, or other virus infections.

Mevof is to be given only by or under the direct supervision of your doctor.

Mevof indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Mevof Tablets, USP and other antibacterial drugs, Mevof Tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mevof Tablets, USP is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section.

Culture and susceptibility testing

Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to Mevof Tablets, USP. Therapy with Mevof Tablets, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.

As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Mevof Tablets, USP. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.

Nosocomial Pneumonia

Mevof Tablets, USP is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended.

Community-Acquired Pneumonia: 7–14 day Treatment Regimen

Mevof Tablets, USP is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae.

MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.

Community-Acquired Pneumonia: 5-day Treatment Regimen

Mevof Tablets, USP is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae

Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens

Mevof Tablets, USP is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.

Acute Bacterial Exacerbation of Chronic Bronchitis

Mevof Tablets, USP is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.

Complicated Skin and Skin Structure Infections

Mevof Tablets, USP is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis.

Uncomplicated Skin and Skin Structure Infections

Mevof Tablets, USP is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes.

Chronic Bacterial Prostatitis

Mevof Tablets, USP is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis.

Complicated Urinary Tract Infections: 5-day Treatment Regimen

Mevof Tablets, USP is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis.

Complicated Urinary Tract Infections: 10-day Treatment Regimen

Mevof Tablets, USP is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa.

Acute Pyelonephritis: 5 or 10-day Treatment Regimen

Mevof Tablets, USP is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia.

Uncomplicated Urinary Tract Infections

Mevof Tablets, USP is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus.

Inhalational Anthrax (Post-Exposure)

Mevof Tablets, USP is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of Mevof Tablets, USP is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Mevof has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of Mevof in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged Mevof therapy should only be used when the benefit outweighs the risk.

Plague

Mevof Tablets, USP is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of Mevof could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an

efficacy study conducted in animals.

How should I use Mevof?

Use Mevof solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • Mevof solution comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Mevof solution refilled.
  • Take Mevof solution by mouth on an empty stomach at least 1 hour before or 2 hours after eating.
  • Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.
  • Drinking extra fluids while you are taking Mevof solution is recommended. Check with your doctor for instructions.
  • Do not take a product that has magnesium, aluminum, calcium, zinc, or iron in it within 2 hours before or 2 hours after you take Mevof solution. Examples of these products include certain antacids, multivitamins, quinapril, and calcium-fortified orange juice. Check with your doctor or pharmacist if you have a question about whether you should separate Mevof solution from a certain food or product.
  • If you also take sucralfate or didanosine, do not take them within 2 hours before or 2 hours after taking Mevof solution. Check with your doctor if you have questions.
  • Mevof solution works best if it is taken at the same time each day.
  • To clear up your infection completely, take Mevof solution for the full course of treatment. Keep taking it even if you feel better in a few days.
  • Do not miss any doses of Mevof solution. If you miss a dose of Mevof solution, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once or more than 1 dose in 1 day.

Ask your health care provider any questions you may have about how to use Mevof solution.

Uses of Mevof in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Mevof is used to treat bacterial infections of the respiratory tract, urinary tract, ear, tooth and prostate gland. It is also used to treat skin and soft tissue infections, anthrax and plague.

Mevof description

Each tablet contains levofloxacin 250 mg as active ingredient corresponding to Mevof hemihydrate 256.23 mg.

Mevof also contains the following inactive ingredients: Sodium chloride; sodium hydroxide; hydrochloric acid (qs: pH 4.8) and water for injection for a volume of 100 mL (Na+ concentration: 154 mmol/L).

Mevof is a synthetic broad-spectrum antibacterial agent for oral and IV administration. Chemically, Mevof, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. Mevof is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate.

Its empirical formula is C18H20FN3O4·½H2O and its molecular weight is 370.38.

Mevof is a light yellowish-white to yellow-white crystal or crystalline powder. The molecule exists as a zwitterion at the pH conditions in the small intestine. The data demonstrate that from pH 0.6-5.8, the solubility of Mevof is essentially constant (approximately 100 mg/mL). Mevof is considered soluble to freely soluble in this pH range, as defined by USP nomenclature. Above pH 5.8, the solubility increases rapidly to its maximum at pH 6.7 (272 mg/mL) and is considered freely soluble in this range. Above pH 6.7, the solubility decreases and reaches a minimum value (about 50 mg/mL) at a pH of approximately 6.9. Mevof has the potential to form stable coordination compounds with many metal ions. This in vitro chelation potential has the following formation order: A1+3 > Cu+2 > Zn+2 > Mg+2 > Ca+2.

Mevof dosage

sponsored

Dosage in Adult Patients with Normal Renal Function

The usual dose of Mevof Tablets, USP is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1.

These recommendations apply to patients with creatinine clearance ≥ 50 mL/min. For patients with creatinine clearance <50 mL/min, adjustments to the dosing regimen are required.

Dosage in Pediatric Patients

The dosage in pediatric patients ≥ 6 months of age is described below in Table 2.

Dosage Adjustment in Adults with Renal Impairment

Administer Mevof Tablets, USP with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of Mevof may be reduced.

No adjustment is necessary for patients with a creatinine clearance ≥ 50 mL/min.

In patients with impaired renal function (creatinine clearance <50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of Mevof due to decreased clearance.

Table 3 shows how to adjust dose based on creatinine clearance.

Drug Interaction With Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins

Mevof Tablets

Mevof Tablets, USP should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable/buffered tablets or the pediatric powder for oral solution.

Administration Instructions

Food and Mevof Tablets, USP

Mevof Tablets, USP can be administered without regard to food.

Hydration for Patients Receiving Mevof Tablets, USP

Adequate hydration of patients receiving oral Mevof Tablets, USP should be maintained to prevent the formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones.

Mevof interactions

See also:
What other drugs will affect Mevof?

sponsored

Chelation Agents : Antacids, Sucralfate, Metal Cations, Multivitamins Mevof

Oral Solution

While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of Mevof

Oral Solution with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of Mevof, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine may substantially interfere with the gastrointestinal absorption of Mevof, resulting in systemic levels considerably lower than desired. These agents should be taken at least two hours before or two hours after oral Mevof administration.

Warfarin

No significant effect of Mevof on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on Mevof absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that Mevof enhances the effects of warfarin. Elevations of the prothrombin time in the setting of concurrent warfarin and Mevof use have been associated with episodes of bleeding. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if Mevof is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding.

Antidiabetic Agents

Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered.

Non-Steroidal Anti-Inflammatory Drugs

The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including Mevof, may increase the risk of CNS stimulation and convulsive seizures.

Theophylline

No significant effect of Mevof on the plasma concentrations, AUC, and other disposition parameters for theophylline was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of theophylline on Mevof absorption and disposition was observed. However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when Mevof is co-administered. Adverse reactions, including seizures, may occur with or without an elevation in serum theophylline levels.

Cyclosporine

No significant effect of Mevof on the peak plasma concentrations, AUC, and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when coadministered with some other fluoroquinolones. Mevof Cmax and ke were slightly lower while Tmax and t½ were slightly longer in the presence of cyclosporine than those observed in other studies without concomitant medication. The differences, however, are not considered to be clinically significant. Therefore, no dosage adjustment is required for Mevof or cyclosporine when administered concomitantly.

Digoxin

No significant effect of Mevof on the peak plasma concentrations, AUC, and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Mevof absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for Mevof or digoxin is required when administered concomitantly.

Probenecid And Cimetidine

No significant effect of probenecid or cimetidine on the C of Mevof was observed in a clinical study involving healthy volunteers. The AUC and t½ of Mevof were higher while CL/F and CLR were lower during concomitant treatment of Mevof with probenecid or cimetidine compared to Mevof alone. However, these changes do not warrant dosage adjustment for Mevof when probenecid or cimetidine is co-administered.

Interactions With Laboratory Or Diagnostic Testing

Some fluoroquinolones, including Mevof, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. Confirmation of positive opiate screens by more specific methods may be necessary.

Mevof side effects

See also:
What are the possible side effects of Mevof?

Serious and Otherwise Important Adverse Reactions

The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:

  • Tendon Effects
  • Exacerbation of Myasthenia Gravis
  • Hypersensitivity Reactions
  • Other Serious and Sometimes Fatal Reactions
  • Hepatotoxicity
  • Central Nervous System Effects
  • Clostridium difficile-Associated Diarrhea
  • Peripheral Neuropathy that may be irreversible
  • Prolongation of the QT Interval
  • Musculoskeletal Disorders in Pediatric Patients
  • Blood Glucose Disturbances
  • Photosensitivity/Phototoxicity [see
  • Development of Drug Resistant Bacteria

Hypotension has been associated with rapid or bolus intravenous infusion of Mevof. Mevof should be infused slowly over 60 to 90 minutes, depending on dosage.

Crystalluria and cylindruria have been reported with quinolones, including Mevof. Therefore, adequate hydration of patients receiving Mevof should be maintained to prevent the formation of a highly concentrated urine.

Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below reflect exposure to Mevof in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was < 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with Mevof for a wide variety of infectious diseases. Patients received Mevof doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily. Treatment duration was usually 3 to 14 days, and the mean number of days on therapy was 10 days.

The overall incidence, type and distribution of adverse reactions was similar in patients receiving Mevof doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of Mevof due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose. The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily nausea (0.6%); vomiting (0.4%); dizziness (0.3%); and headache (0.2%). The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily nausea (0.6%), vomiting (0.5%); dizziness (0.3%); and headache (0.3%).

Adverse reactions occurring in ≥1% of Mevof-treated patients and less common adverse reactions, occurring in 0.1 to <1% of Mevof-treated patients, are shown in Table 6 and Table 7, respectively. The most common adverse drug reactions (≥3%) are nausea, headache, diarrhea, insomnia, constipation, and dizziness.

In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment with quinolones, including Mevof. The relationship of the drugs to these events is not presently established.

Postmarketing Experience

Table 8 lists adverse reactions that have been identified during post-approval use of Mevof. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.

Mevof contraindications

See also:
What is the most important information I should know about Mevof?

Patients hypersensitive to Mevof or any other quinolones or any excipients of Mevof. Patients with epilepsy and those with history of tendon disorder related to fluoroquinolone administration.

Use in pregnancy: Mevof caused no impairment of fertility or reproductive performance in rats at oral doses as high as 360 mg/kg/day. It was not teratogenic in rats at oral doses as high as 810 mg/kg/day or at IV dose up to 160 mg/kg/day. No teratogenicity was observed when rabbits were dosed orally as high as 50 mg/kg/day.

In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, Mevof must not be used in pregnant women or women suspected of being pregnant.

Use in lactation: In the absence of human data and due to the experimental risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, Mevof must not be used in breastfeeding women.

Use in children: Safety and effectiveness in pediatric patients and adolescents <16 years have not been established. Quinolones, including Mevof, cause arthropathy and osteochondrosis in juvenile animals of several species.

Use in

Elderly: The pharmacokinetic properties of Mevof in younger adults and elderly do not differ significantly when creatinine clearance is taken into consideration. However, since Mevof is known to be substantially excreted by the kidney, the risk of toxic reactions to Mevof may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.



Active ingredient matches for Mevof:

Levofloxacin in India.


Unit description / dosage (Manufacturer)Price, USD
250 mg x 100's$ 7.94
500 mg x 40's$ 5.40
750 mg x 100's$ 19.05
Mevof 250mg TAB / 100$ 7.94
Mevof 500mg TAB / 40$ 5.40
Mevof 750mg TAB / 100$ 19.05
MEVOF tab 250 mg x 10's (Arvincare)$ 0.79
MEVOF tab 500 mg x 10's (Arvincare)$ 1.35
MEVOF tab 750 mg x 10's (Arvincare)$ 1.90
Mevof 250mg TAB / 100$ 7.94
Mevof 500mg TAB / 40$ 5.40
Mevof 750mg TAB / 100$ 19.05

List of Mevof substitutes (brand and generic names):

250 mg x 5's (Glenmark (Milieus))$ 0.38
500 mg x 5's (Glenmark (Milieus))$ 0.71
750 mg x 5's (Glenmark (Milieus))$ 0.85
Milivo 250mg FC-TAB / 5 (Glenmark (Milieus))$ 0.86
Milivo 500mg FC-TAB / 5 (Glenmark (Milieus))$ 0.71
Milivo 750mg FC-TAB / 5 (Glenmark (Milieus))$ 0.85
MILIVO 250MG TABLET 1 strip / 5 tablets each (Glenmark (Milieus))$ 0.35
MILIVO 500MG TABLET 1 strip / 5 tablets each (Glenmark (Milieus))$ 0.71
MILIVO 750MG TABLET 1 strip / 5 tablets each (Glenmark (Milieus))$ 0.81
MILIVO film-coated tab 250 mg x 5's (Glenmark (Milieus))$ 0.38
MILIVO film-coated tab 500 mg x 5's (Glenmark (Milieus))$ 0.71
Milivo 500mg FC-TAB / 5 (Glenmark (Milieus))$ 0.71
Milivo 250mg FC-TAB / 5 (Glenmark (Milieus))$ 0.86
Milivo 250mg Tablet (Glenmark (Milieus))$ 0.07
Milivo 500mg Tablet (Glenmark (Milieus))$ 0.14
Milivo 750mg Tablet (Glenmark (Milieus))$ 0.16
500 mg x 100's (Mint)
Mintoflox 500mg TAB / 100 (Mint)
MINTOFLOX tab 500 mg x 10's (Mint)
Mintoflox 500mg TAB / 100 (Mint)
MLEVO 125MG SUSPENSION 1 bottle / 60 ML suspension each (Moraceae Pharmaceuticals Pvt Ltd)$ 0.91
MLEVO 500MG TABLET 1 strip / 10 tablets each (Moraceae Pharmaceuticals Pvt Ltd)$ 1.57
Mlevo 500mg Tablet (Moraceae Pharmaceuticals Pvt Ltd)$ 0.16
500 mg x 10's (ModHike)
Mod's Levo 500mg TAB / 10 (ModHike)
MOD'S LEVO tab 500 mg x 10's (ModHike)
250 mg x 10's (Acinom Healthcare)$ 0.71
500 mg x 10's (Acinom Healthcare)$ 1.25
750 mg x 10's (Acinom Healthcare)$ 1.83
Monlevoxa 250mg TAB / 10 (Acinom Healthcare)$ 0.71
Monlevoxa 500mg TAB / 10 (Acinom Healthcare)$ 1.25
Monlevoxa 750mg TAB / 10 (Acinom Healthcare)$ 1.83
MONLEVOXA tab 250 mg x 10's (Acinom Healthcare)$ 0.71
MONLEVOXA tab 500 mg x 10's (Acinom Healthcare)$ 1.25
MONLEVOXA tab 750 mg x 10's (Acinom Healthcare)$ 1.83
Monlevoxa 250mg TAB / 10 (Acinom Healthcare)$ 0.71
Monlevoxa 500mg TAB / 10 (Acinom Healthcare)$ 1.25
Monlevoxa 750mg TAB / 10 (Acinom Healthcare)$ 1.83
200 mg x 100's (Captab)
400 mg x 100's (Captab)
Monoflox 200mg TAB / 100 (Captab)
Monoflox 400mg TAB / 100 (Captab)
MONOFLOX 250MG TABLET 1 strip / 5 tablets each (Captab)$ 0.31
MONOFLOX 500MG TABLET 1 strip / 5 tablets each (Captab)$ 0.59
MONOFLOX 750MG TABLET 1 strip / 5 tablets each (Captab)$ 0.81
MONOFLOX tab 200 mg x 10's (Captab)
MONOFLOX tab 400 mg x 10's (Captab)
Monoflox 200mg TAB / 100 (Captab)
Monoflox 400mg TAB / 100 (Captab)
Monoflox 250mg Tablet (Captab)$ 0.06
Monoflox 500mg Tablet (Captab)$ 0.12
Monoflox 750mg Tablet (Captab)$ 0.16
Monoflox Tab 250mg TAB / 5 (Centaur)$ 0.31
Monoflox Tab 500mg TAB / 5 (Centaur)$ 0.58
Monoflox Tab 750mg TAB / 5 (Centaur)$ 0.84
250 mg x 5's (Centaur)$ 0.31
500 mg x 5's (Centaur)$ 0.58
750 mg x 5's (Centaur)$ 0.84
MONOFLOX TAB tab 250 mg x 5's (Centaur)$ 0.31
MONOFLOX TAB tab 500 mg x 5's (Centaur)$ 0.58
MONOFLOX TAB tab 750 mg x 5's (Centaur)$ 0.84

References

  1. DailyMed. "LEVOFLOXACIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "LEVOFLOXACIN". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "LEVOFLOXACIN". http://www.drugbank.ca/drugs/DB01137 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Mevof are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Mevof. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 17 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2019 ndrugs.com All Rights Reserved